Oncology Advances is dedicated to improving the diagnosis and treatment of human malignancies, advancing the understanding of molecular mechanisms underlying oncogenesis, and promoting translation from bench to bedside of oncological sciences. The aim of Oncology Advances is to publish peer-reviewed, high-quality articles in all aspects of translational and clinical studies on human cancers, as well as cutting-edge preclinical and clinical research of novel cancer therapies. 

Oncology Advances adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open access journal are subject to the same rigorous peer-review and quality control as in scholarly subscription journals.

Oncology Advances recognizes the distinct advantages of using an open access publication model to timely disseminate innovative and important research findings. Unrestricted free access to our publications is anticipated to foster intellectual discourse across geographic and disciplinary boundaries. To support the success of our open access approach, we ensure the integrity and high quality of research published in our journal by practicing a rigorous peer review process and by following strict guidelines for ethics in publication and in conduct of the scientific process.

All manuscripts submitted to Oncology Advances must meet the following criteria for publication:

• Topics with timely relevance to the general field or specialties in basic and clinical medicine;
• A must-have section of “hypothesis/ future direction/ prospect/ prediction” included for all research and review articles;
• Results and findings that have not been previously published elsewhere;
• Research performed with adherence to accepted global standards for ethics in the scientific process;
• Ethical reporting of data to protect the rights and privacy of study participants;
• Appropriate statistical analyses, with sufficient descriptions of all statistical methods used;
• Conclusions supported by the data presented;
• All funding sources and their roles cited;
• For clinical trials, the registration number cited;
• Manuscript written in standard American (US) English and formatted according to the journal-specific guidelines;
• No instances of textual plagiarism, including ‘text recycling/self-plagiarism”.

Oncology Advances adopts the open access publishing model. Revenues are generated from article processing charges (APC), permission fees, and reprints.